Bupropion SR vs placebo for smoking cessation in health care professionals

被引：25

作者：

Zellweger, JP

Boeleskei, PL

Carrozzi, L

Sepper, R

Sweet, R

Hider, AZ

机构：

[1] Univ Lausanne, Med Poliklin, CH-10011 Lausanne, Switzerland

[2] Inst Smokers Counseling & Smoking Cesat, Munich, Germany

[3] Univ Pisa, Cardiac & Thorac Dept, Pisa, Italy

[4] N Estonian Reg Hosp, Tallinn, Estonia

[5] GlaxoSmithKline Res & Dev Ltd, Greenford, Middx, England

来源：

AMERICAN JOURNAL OF HEALTH BEHAVIOR | 2005年 / 29卷 / 03期

关键词：

bupropion SR; healthcare professionals; smoking cessation;

D O I：

10.5993/AJHB.29.3.5

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Objective: To evaluate bupropion SR for smoking cessation in physicians and nurses. Methods: This double-blind prospective 26-center, 12-country trial randomized 687 subjects to smoking cessation counselling with bupropion SR or placebo for 7 weeks. The participants were followed for 52 weeks. Results: Bupropion SR was superior to placebo (50% vs 40%, P=0.013) on the 4-week primary outcome variable. Due to a high placebo response in this health care population, statistical differences were not maintained after treatment was discontinued. Conclusions: Bupropion SR is effective and well tolerated in health care professionals. Relapse prevention measures are needed to attain long-term abstinence.

引用

页码：240 / 249

页数：10

共 31 条

[11]

Grossman DW, 1999, B WORLD HEALTH ORGAN, V77, P315

[12] Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation - A randomized, controlled trial [J].